Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 0.59 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22172484 | 0.93 | GABBR2 (0.72) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL7822991 | 0.93 | GABBR2 (0.72) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL7031963 | 0.90 | GABBR2 (0.74) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL12883209 | 0.89 | GABBR2 (0.53) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL6662884 | 0.87 | GABBR2 (0.51) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL11080642 | 0.83 | ALDH1A1 (0.47) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL4617540 | 0.83 | CYP2C19 (0.55) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL22504119 | 0.83 | GABBR2 (0.47) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL390453 | 0.82 | CYP2C9 (0.50) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL19810879 | 0.82 | CYP2C9 (0.50) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874804-B1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FINE CHEMICALS CORP PROPRIETAR (ZA) | 2001-06-13 | — | — | EP | claimed |
| US-6051734-A | REACTING RACEMIC 3-(P-CHLOROPHENYL)-GLUTARAMIDE DISSOLVED IN A SUITABLE SOLVENT WITH S(-)A-METHYLBENZYLAMINE, DISSOLVING PRECIPITATE | FARMARC NEDERLAND B.V. (NL) | 2000-04-18 | — | — | US | claimed |
| EP-0874804-A1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FARMARC NEDERLAND BV (NL) | 1998-11-04 | — | — | EP | claimed |
| WO-1997022578-A1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FARMARC NEDERLAND B.V. (NL) | 1997-06-26 | — | — | WO | claimed |
| WO-2020141141-A1 | COCRYSTALS OF (R)-BACLOFEN | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2020-07-09 | — | — | WO | disclosed |
| EP-3674287-A1 | COCRYSTALS OF (R)-BACLOFEN | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2020-07-01 | — | — | EP | disclosed |
| CN-102753702-B | Process for preparing optically active 3-substituted glutaric acid monoamides | KANEKA CORP | 2015-02-11 | — | — | CN | disclosed |
| EP-2518050-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-SUBSTITUTED GLUTARIC ACID MONOAMIDE | Kaneka Corporation (JP) | 2012-10-31 | — | — | EP | disclosed |
| CN-102753702-A | Process for preparing optically active 3-substituted glutaric acid monoamides | KANEKA CORP | 2012-10-24 | — | — | CN | disclosed |
| US-8273917-B2 | Method for preparing chiral baclofen | SCI PHARMTECH, INC. (TW) | 2012-09-25 | — | — | US | disclosed |
| EP-2460885-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 3-SUBSTITUTED GLUTARIC ACID MONOAMIDE | Kaneka Corporation (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120029230-A1 | METHOD FOR PREPARING CHIRAL BACLOFEN | SCI PHARMTECH, INC. (TW) | 2012-02-02 | — | — | US | disclosed |
| EP-0874804-A1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FARMARC NEDERLAND BV (NL) | 1998-11-04 | — | — | EP | disclosed |
| EP-0874804-A1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FARMARC NEDERLAND BV (NL) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997022578-A1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FARMARC NEDERLAND B.V. (NL) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997022578-A1 | A PROCESS FOR THE OPTICAL RESOLUTION OF 3-(P-CHLOROPHENYL)-GLUTARAMIDE | FARMARC NEDERLAND B.V. (NL) | 1997-06-26 | — | — | WO | disclosed |
| EP-0024776-B1 | 4-PHENYL AND 5-PHENYL-1,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES, AND PROCESS FOR PREPARING SAID DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4322421-A | 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydro-pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4261995-A | DISORDERS OF CENTRAL NERVOUS SYSTEM AND CARDIOVASCULAR SYSTEM; HYPOTENSIVE | SYNTEX (U.S.A.) INC. (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0024776-A1 | 4-Phenyl and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives, pharmaceutical compositions containing said derivatives, and process for preparing said derivatives | SYNTEX (U.S.A.) INC. (US) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029230-A1 | METHOD FOR PREPARING CHIRAL BACLOFEN | GABRE, GABRB2, GABRB3 | GABBR2 5/4885GABBR1 7/4885LMNA 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.